Corticosteroid Therapy Guidelines

Introduction to Corticosteroid Therapy

The American Association for the Study of Liver Diseases recommends prednisone 60 mg daily (monotherapy) or 30 mg daily with azathioprine (combination therapy) for autoimmune hepatitis, with prednisolone used interchangeably in equivalent doses 1, 5
The European League Against Rheumatism recommends oral prednisone 12.5-25 mg daily as the standard initial therapy for polymyalgia rheumatica, with IM methylprednisolone 120 mg every 3 weeks offered as an alternative when oral administration is problematic 2

Methylprednisolone is 1.25 times more potent than prednisone, meaning 4 mg of methylprednisolone equals approximately 5 mg of prednisone 3
Practical conversion examples include: prednisone 60 mg daily = methylprednisolone 48 mg daily, prednisone 30 mg daily = methylprednisolone 24 mg daily, and prednisone 0.5 mg/kg daily = methylprednisolone 0.4 mg/kg daily 3

Methylprednisolone can be given orally, IV, or IM, making it the necessary choice when patients cannot tolerate oral medications or require parenteral therapy 4
The American College of Rheumatology recommends methylprednisolone for severe disease requiring hospitalization, patients unable to take oral medications, pulse therapy protocols, adherence concerns, and pulmonary conditions 4

The American Association for the Study of Liver Diseases recommends prednisone as the standard for autoimmune hepatitis, with a combination regimen of prednisone and azathioprine reducing corticosteroid-related side effects from 44% to 10% 1, 5
The European League Against Rheumatism recommends oral prednisone 12.5-25 mg daily as the standard initial therapy for polymyalgia rheumatica 2
Methylprednisolone is preferred for acute severe asthma, lupus nephritis, acute graft-versus-host disease, severe pemphigus, and ARDS 4

Methylprednisolone demonstrates greater tissue penetration in pulmonary conditions and longer residence time in lung tissue, though clinical superiority remains theoretical 4

Both drugs have similar biological half-lives (12-36 hours), but methylprednisolone pulse therapy produces faster clinical responses (approximately 4.7 days) compared to standard oral prednisone regimens 6
Disease control with methylprednisolone pulse therapy typically occurs within 7-10 days, representing time to clinical effect rather than drug duration 6

The American Association for the Study of Liver Diseases recommends prednisone 60 mg daily (monotherapy) or 30 mg daily (with azathioprine) for autoimmune hepatitis 1
The European League Against Rheumatism recommends oral prednisone 12.5-25 mg daily as the standard initial therapy for polymyalgia rheumatica 2
Methylprednisolone dosing ranges from 4-48 mg daily for oral administration, with pulse therapy ranging from 250-1000 mg IV daily for 2-5 days 4

Both drugs require identical tapering approaches to avoid adrenal insufficiency and disease flare 1, 4
The American Association for the Study of Liver Diseases recommends a standard taper for prednisone, with reductions of 5 mg weekly until 10 mg/day, then 2.5 mg weekly until 5 mg/day, and finally 1 mg every 4 weeks until discontinuation 1

Both drugs share identical side effect profiles at equivalent doses, including hyperglycemia, infection risk, osteoporosis, hypertension, and HPA axis suppression 1, 4
The combination regimen of prednisone with azathioprine reduces corticosteroid-related side effects from 44% to 10% compared to high-dose prednisone monotherapy 1

The American Association of Clinical Endocrinologists recommends identical bone protection requirements for both drugs, including calcium and vitamin D supplementation with bisphosphonates for patients taking prednisone ≥7.5 mg daily (or methylprednisolone ≥6 mg daily) for ≥3 months 3

The American Association for the Study of Liver Diseases recommends baseline and annual bone mineral densitometry for long-term therapy, as well as hyperglycemia monitoring, infection surveillance, and HPA axis suppression monitoring 1, 4, 6

The American College of Rheumatology recommends prednisone as the practical choice for chronic therapy due to its significant cost-effectiveness and universal availability 1, 5
IM methylprednisolone may not be available in all countries, limiting its use as an alternative to oral therapy 2